Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia
Enrollment ongoing in pediatric dose groups Interim data of all adult dose groups expected in 2H of 2020 GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of
View HTML
Toggle Summary AGTC Announces Completion of Enrollment in the Two Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Pricing of $32,500,000 Public Offering of Common Stock
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
View HTML
Toggle Summary AGTC Announces Proposed Public Offering of Common Stock
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia
–Encouraging preliminary signs of biologic activity and a favorable safety profile are outcomes that are clinically relevant to patients – Enrollment ongoing in additional dose groups, which will include pediatric patients; interim data from these additional dose groups expected in 2H of 2020 –
View HTML
Toggle Summary AGTC to Host Conference Call and Webcast on January 23 at 8:00 am ET to Discuss Achromatopsia Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Agenda for R&D Day on January 28, 2020 in New York
Management and External Thought Leaders to Discuss Data from XLRP and ACHM Phase 1/2 Clinical Trials Webcast Scheduled from 7:30 am – 12:00 pm ET GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
View HTML
Toggle Summary AGTC Reports Positive Six-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa
- Data suggest durable and meaningfully improvements in central visual sensitivity - Secondary data showed encouraging improvements in Best Corrected Visual Acuity - All patients dosed continue to demonstrate a favorable safety profile - Company plans to initiate pivotal trial by the end of 2020 -
View HTML
Toggle Summary AGTC to Host Conference Call and Webcast on January 9 at 8:00 am ET to Discuss X-Linked Retinitis Pigmentosa Interim Six-Month Data from the Dose Expansion Cohort of its Ongoing Phase 1/2 Clinical Trial
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Visionary science for life changing cures.